论文部分内容阅读
摩萨青霉素(moxalactam)是一种新的、经静脉给药的半合成苯唑-β-青霉素抗菌剂。作者对临床上证明细菌感染并需系统抗菌治疗的93例成人患者作了111次感染治疗研究。摩萨青霉素剂量为每8小时静注500mg至每4小时静注2.0g,疗程据各种感染而定。结果细菌性脑膜炎3例中,2例为肺炎球菌性,疗效好;另1例为神经外科术后产气大肠杆菌性,疗效也好,但于治疗的第9天死于肺栓塞。肺炎病人14例,治愈10例,致病菌为流感杆菌、金黄色葡萄球菌、肺炎链球菌或绿脓杆菌。尿道感染30例中17
Moxalactam is a new, semi-synthetic, oxazo-β-penicillin antibacterial agent that is administered intravenously. The authors made 111 infection-treatment studies of 93 adult patients clinically proven to have bacterial infections and needed systemic antibacterial therapy. Mosaza penicillin dose of intravenous infusion of 500mg every 8 hours to 4 hours intravenously 2.0g, treatment according to various infections may be. Results Among the 3 cases of bacterial meningitis, 2 were pneumococcal with good curative effect. The other 1 case was gas-producing Escherichia coli after neurosurgery. The efficacy was good, but died of pulmonary embolism on the 9th day of treatment. 14 cases of pneumonia patients, 10 cases of cure, pathogenic bacteria are influenza bacilli, Staphylococcus aureus, Streptococcus pneumoniae or Pseudomonas aeruginosa. Urinary tract infection in 30 cases 17